Plus Therapeutics (PSTV) Non-Current Debt (2010 - 2022)

Plus Therapeutics (PSTV) reported Non-Current Debt of $3.8 million for Q4 2022, down 24.36% year-over-year from $5.0 million in Q4 2021, and down 7.84% quarter-over-quarter from $4.1 million in Q3 2022.

Plus Therapeutics (PSTV) Non-Current Debt (2010 - 2022) Analysis & Trends

Plus Therapeutics (PSTV) has 10 years of Non-Current Debt data on file, last reported at $3.8 million in Q4 2022.

  • Non-Current Debt for Q4 2022 came in at $3.8 million, down 24.36% year-over-year; the trailing twelve-month figure through Dec 2022 was $3.8 million (down 24.36% YoY), and the FY2022 annual result was $3.8 million, down 24.36% from the prior year.
  • Non-Current Debt declined to $3.8 million in Q4 2022 per PSTV's latest filing, from $4.1 million in the prior quarter.
  • Over five years, Non-Current Debt peaked at $5.0 million in Q4 2021 and troughed at $3.8 million in Q4 2022.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Debt (Qtr)
1 Alterity Therapeutics 719,706.53 Bn 719,706.50 Bn - -
2 Belite Bio 55,800.00 Bn 55,800.00 Bn - -
3 Quantum Biopharma 18,182.30 Bn 18,182.29 Bn - -
4 Legend Biotech 3,154.00 Bn 3,153.71 Bn 242.10 Mn 319.10 Mn
5 Akari Therapeutics 1,844.30 Bn 1,844.29 Bn - -
6 Evaxion A 1,567.96 Bn 1,567.94 Bn - -
7 Psyence Biomedical 251.43 Bn 251.42 Bn - -
8 Vertex Pharmaceuticals 112.56 Bn 105.31 Bn 2.59 Bn -
9 Abivax 94.37 Bn 94.37 Bn - -
10 Plus Therapeutics 37.48 Mn 22.37 Mn - -

Historic Data

Download Data
DateValue
Dec 31, 2022 3.79 Mn
Dec 31, 2022 3.79 Mn
Sep 30, 2022 4.11 Mn
Sep 30, 2022 4.11 Mn
Jun 30, 2022 4.42 Mn
Jun 30, 2022 4.42 Mn
Mar 31, 2022 4.72 Mn
Mar 31, 2022 4.72 Mn
Dec 31, 2021 5.01 Mn
Dec 31, 2021 5.01 Mn
Jun 30, 2017 7.77 Mn
Jun 30, 2017 7.77 Mn
Mar 31, 2017 9.40 Mn
Mar 31, 2017 9.40 Mn
Dec 31, 2016 11.01 Mn
Dec 31, 2016 11.01 Mn
Sep 30, 2016 12.13 Mn
Sep 30, 2016 12.13 Mn
Jun 30, 2016 13.66 Mn
Jun 30, 2016 13.66 Mn